

DRUG UTILIZATION REVIEW BOARD
April 21, 2021
MO HealthNet (MHD)
VIA WEBEX ONLY

Committee Members Present:

Susan Abdel-Rahman, PharmD, Chair
Kenneth Haller, MD
Charlene Heyde, RPH
Rick Kegler, PharmD, MBA
Ginger Nicol, MD, CEDS
Lisa Pierce, MD
Stacy Mangum, PharmD
Jennifer Passanise, FNP

Committee Members Absent:

Sandra Bollinger, PharmD

MO HealthNet Staff Present:

Joshua Moore, PharmD, Director of
Pharmacy
Mark Roaseau, R.Ph, Clinical Pharmacist
Angela Wilson, Pharmacy Operations
Manager
Elizabeth Sissom, RN, Clinical
Management
Lisa E. Smith, Program Development
Specialist
Timothy Kling, MD, Acting Medical
Director
Elizabeth Short, Program Development
Specialist
Connie Sutter, Fiscal Manager
Jackie Hickman, Drug Rebate Unit
Supervisor

Keri Ballew, Drug Rebate Medicaid
Specialist
Olivia Rush, PharmD, Program Integrity
Pharmacist

Contractors in Attendance:

Chelsea Pendleton, RN, BSN, Wipro
Geri Roling, RN, Wipro
April Ash, PharmD, Conduent
Blake Shrout, PharmD, AAHIVP,
Conduent
Jennifer Colozza, PharmD, Conduent
Karen Powell, PharmD, Conduent
Katie Wilbers, PharmD, Conduent
Luke Boehmer, PharmD, Conduent
Mary-Beth Plum, PharmD, Conduent
Megan Fast, PharmD, Conduent
Sandra Kapur, PharmD, Conduent
Serena Barden, PharmD, BCPS,
Conduent

Others Attending:

Andrew Harsh
Ashlee
Ben
Brent Young
Bryan Moore
Cheryl M
Debbie Brokaw
Emma Selm-Keck

Eric Gardner
Erin Hohman
Evan Rushing
Gina Heinen
Holly Budlong
James Baumann
Jessica Petrie
John Bullard
Jones Guest
Jordan Potter
Joy Farina
Karen Floeder
Kurt
Mark Kaiser
Melissa Basil
Mholmes1
Michele Shirley
Philip King
Rick Dabner
Rick Kegler
Ricki Roberson
Rob Hansen
Susie Moroney
Thomas Yelle
Tom Guyer

<p>Welcome, Introductions and Opening Remarks</p>	<p>Susan Abdel-Rahman, Board Chair, called the meeting to order.</p> <p>Joshua Moore, MHD Director of Pharmacy, introduced himself, new Conduent team members Blake Shroust and Serena Barden and facilitated the meeting on behalf of the MHD.</p>
<p>Minutes Review</p>	<p>Discussion: Minutes were reviewed from the January 2021 meeting.</p> <p>Decision: The Board voted to accept these approved minutes with no additional revisions.</p>
<p>Pharmacy Program and Budget Update</p>	<p>Elizabeth Short and Joshua Moore presented a brief power point of the Pharmacy Program and Budget Updates. Information presented included:</p> <ul style="list-style-type: none"> - March 2021 Eligibles by Group - July 2020 – March 2021 Expenditures by Enrollment Group - July 2020 – March 2021 Expenditures by Service - FY21 Pharmacy Spend vs July 2020 – March 2021 Total Medicaid Spend - FY21 July 2020 – April 2021 Pharmacy Expenditures - Top 4 Drug Classes per Fiscal Year - July 2020 – April 2021 Rare Disease Expenditures - FY19 – FYTD2021 Rare Disease Expenditures - Sedative Hypnotics PDL Edit Changes July 2020 - Pharmacist as Other Licensed Professionals - COVID Vaccine/Testing Billing and Reimbursement - Tamiflu Utilization Comparison Year over Year
<p>Old Business</p>	
<p>Old Business</p>	<p>Joshua Moore discussed the Edit Implementation Schedule and the criteria for Previously Approved Clinical Edits, Step Therapies and Prior Authorizations.</p> <p>These handouts were also provided to all attendees and will be posted to the Division's web page: https://dss.mo.gov/mhd/cs/advisory/dur/meeting.htm</p>

New Business	
New Drug Review	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore reviewed the new products identified for the quarter and the recommended status within the pharmacy program. <ul style="list-style-type: none"> o A listing of products recommended for open access, clinical edit, preferred drug list (PDL), or continue prior authorization was emailed to the Board for discussion and action. - No other discussion. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
Clinical & Fiscal Edits With No Annual Changes	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edits for discussion to the Board which included: <ul style="list-style-type: none"> o Acne or Rosacea, Select Topical Agents Clinical Edit o Givlaari Clinical Edit o Megestrol Clinical Edit o Sickle Cell Disease Clinical Edit o Systemic Antifungals Clinical Edit o Zulresso Clinical Edit - No other discussion. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators Clinical Edit	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. <p>Decision: The Board voted to accept the recommended criteria with no additional revisions and added to the block vote.</p>

<p>Clobazam Agents Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - Discussion arose on the potential knowledge gain received with the two claims of Sympazan. - Reminder was given on the third party liability process and how not all claims hit MHD edits due to primary insurance. <ul style="list-style-type: none"> o Seen in many other disease states (i.e., SMA/CAR-T) which makes it difficult to predict true drug costs. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p>Fabry Disease Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p>Nocturnal Polyuria Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p>Opioids, Single Agents Short Acting Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - Discussion arose on the high number of tablets allowed in the opioid naive dose charts (i.e., – codeine sulfate tablets). <ul style="list-style-type: none"> o Recommendation of 8-16 tabs per day was made. o MHD to bring back more information on utilization along with current guidelines on naïve dosing to the next meeting. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>

<p style="text-align: center;">Oxlumo Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p style="text-align: center;">Spravato Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p style="text-align: center;">Preferred Drug List Edits With No Annual Changes</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edits for discussion to the Board which included: <ul style="list-style-type: none"> o Actinic Keratosis Agents, Topical PDL Edit o Antifungals, Oral PDL Edit PDL Edit o Antihistamines, Intranasal PDL Edit o Antihistamines/Decongestant Combinations, Second Generation PDL Edit o Antivirals, Oral PDL Edit o Antivirals, Topical PDL Edit o Benzoyl Peroxide/Antibiotic Combinations PDL Edit o Beta Adrenergic Agents, Long Acting PDL Edit o Beta Adrenergic Agents, Nebulized PDL Edit o Cough/Cold Preparations PDL Edit o Fluoroquinolones, Ophthalmic PDL Edit o Mast Cell Stabilizers, Ophthalmic PDL Edit o NSAIDs, Ophthalmic PDL Edit o Pancreatic Enzymes PDL Edit o Psoriasis Agents, Oral PDL Edit o Psoriasis Agents, Topical PDL Edit o Retinoids, Topical PDL Edit o Ulcerative Colitis Agents, Rectal PDL Edit - No other discussion. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>

<p>Androgenic Agents PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p>Antibiotics, Inhaled PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p>Antifungals, Topical PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p>Antihistamines, Ophthalmic PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p>Antiparasitics, Topical PDL Edit</p>	<p>Discussion:</p> <p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>

<p align="center">Atopic Dermatitis Agents, Immunomodulators, PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - Questions arose on the lower limit for Elidel – specialist currently don't enforce the lower limit for Elidel and the recommendations in the proposal mirror current prescribing habits of MHD providers. - Recommendation to change Eucrisa criteria for those 3mons to 2 years: adequate therapeutic trial of an emollient/moisturizer AND topical low potency corticosteroid OR Elidel due to approved ages and black box warning. <p>Decision: The Board accepted the recommended criteria with the additional revisions above in blue and added to the block vote.</p>
<p align="center">Beta Adrenergics Agents, Short Acting PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - Discussion arose on ways to ease the call burden between pharmacies and providers when MHD requires a specific generic albuterol HFA inhaler. <ul style="list-style-type: none"> o MHD to reach out the Missouri Board of Pharmacy for clarification <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p align="center">COPD Agents PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - Discussion arose on the coverage of Trelegy Elipta and the appropriate steps that need to be taken for approval. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p align="center">Corticosteroids, Inhaled PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>

<p align="center">Corticosteroids, Intranasal PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p align="center">Corticosteroids, Ophthalmic Soft PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p align="center">Corticosteroids, Topical PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p align="center">Epinephrine Agents, Self-Injectable PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - Clarification was provided on how MHD defines a failure of these agents. <ul style="list-style-type: none"> o It was discussed that the same verbiage for a trial/failure was used across all proposals but a participant could very easily receive a non-preferred if required. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p align="center">Fluoroquinolones, Otic PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>

<p>Glaucoma Agents PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p>Hepatitis C Agents PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - Additional information was provided in regards to the State’s Hepatitis Elimination Plan. - No public comment provided. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p>Hereditary Angioedema (HAE) Agents PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p>Leukotriene Receptor Modifiers PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - Discussion arose on the feasibility of switching to another agent within the class if participants have history of an inappropriate diagnosis trying to receive Singulair. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p>Respiratory Monoclonal Antibodies PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>

<p>Ulcerative Colitis, Oral PDL Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Board. - No other discussion. <p>Decision: The Board accepted the recommended criteria with no additional revisions and added to the block vote.</p>
<p>Program Utilization Information – Conduent Update</p>	<p>Jennifer Colozza with Conduent presented the following items for review:</p> <ul style="list-style-type: none"> - Top 25 Drugs by Paid Amount 2nd Quarter 2021 (October, November, December) - Top 25 Drugs by Paid Number 2nd Quarter 2021 (October, November, December) - Call Center User Statistics February 2021 - CyberAccess Logging Information - New Drug Statistics February 2021
<p>DUR Interventions – Conduent Update</p>	<p>Katie Wilbers with Conduent presented the following items for review:</p> <ul style="list-style-type: none"> - Recent Interventions: <ul style="list-style-type: none"> o Post-Traumatic Stress Disorder – mailed October 2020 o High-Risk Influenza – mailed October 2020 o Anticonvulsant Drug Use Evaluation – to be mailed Q1 2021 o Glucagon after visit for Hypoglycemia – to be mailed Q2 2021 - Potential RetroDUR Interventions: <ul style="list-style-type: none"> o Gabapentinoid Drug Use Evaluation - Outcomes: <ul style="list-style-type: none"> o Long-Term use of Opioids and Benzodiazepines
<p>Other Business</p>	<p>Goodbyes and many thanks were said to Kenneth Haller and his 11 years on the Board along with Jackie Hickman and her 27 years of working in the rebate unit.</p>
<p>Closing</p>	<p>Ginger Nicol motioned for the meeting to be adjourned. The meeting was adjourned pursuant to Section 610.021 Subsection (14), (5) RSMo for proceedings required pursuant to a disciplinary order concerning medical, psychiatric, psychological, or alcoholism or drug dependency diagnosis or treatment of specific licensees. The next meeting of the Drug Utilization Review Board is scheduled via WebEx only on Wednesday, July 21, 2021 unless otherwise specified.</p>

Roll Call for April 21, 2021				
	<u>Action Item</u>			
<u>Board Member</u>	January Meeting Minutes	All Recommendations: Block Vote for CE, FE and PDL Edits	Closing	Adjournment
Susan Abdel-Rahman	Y	Y	Y	Y
Charlene Heyde	Y	Y	Y	MY
Sandra Bollinger	A	A	A	A
Kenneth Haller	SY	Y	SY	Y
Lisa Pierce	MY	Y	Y	SY
Jennifer Passanise	Y	Y	A	A
Stacy Mangum	A	SY	Y	Y
Ginger Nicol	Y	Y	MY	Y
Rick Kegler	Y	MY	Y	Y

Roll Call Abbreviations: A-Absent; AL-Alternate; R-Ratify; M-Motion; S-Second; Y-Yes; N-No; AB-Abstain